Open Label Pilot Trial in Adults With Recent-onset T1D to Evaluate the Safety, Diabetes Status and Immune Response of GAD-antigen (Diamyd) Therapy Administered Into Lymph Nodes in Combination With an Oral Vitamin D Regimen
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2018
At a glance
- Drugs GAD65 vaccine (Diamyd) (Primary) ; Ergocalciferol
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Acronyms DIAGNODE; DIAGNODE-1
- 12 Mar 2018 Interim results (n=9) published in a Diamyd Medical AB media release.
- 08 Jan 2018 Interim results (n=4) for 30 month follow-up period, published in a Diamyd Medical AB media release.
- 11 Dec 2017 Results published in the Diamyd Medical Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History